Le Gardeur, Canada

Denis Brouillette


Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 2008

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Denis Brouillette: Innovator in Hemodynamic Reactions

Introduction

Denis Brouillette, located in Le Gardeur, Canada, is a notable inventor recognized for his contribution to the field of medicine through his innovative patent. With a focus on addressing critical health issues, Brouillette's work centers around the use of methylene blue and related compounds to manage exaggerated hemodynamic reactions, specifically in patients undergoing certain medical treatments.

Latest Patents

Brouillette holds a patent titled "Use of methylene blue and related compounds to prevent or reverse an exaggerated hemodynamic reaction." This invention is significant as it relates to the use of methylene blue (MB) or a related compound to prevent or reverse serious conditions such as hypotension, unstable angina, myocardial infarction, or shock. These conditions may arise from the concurrent intake of a phosphodiesterase inhibitor like sildenafil citrate and a nitric oxide donor such as L-arginine or an organic nitrate like nitroglycerin.

Career Highlights

Brouillette is affiliated with the Montreal Heart Institute, where he applies his expertise in cardiovascular medicine to drive research and innovation. His pioneering efforts in the medical field underscore his commitment to improving patient outcomes through novel therapeutic strategies.

Collaborations

Throughout his career, Brouillette has collaborated with esteemed colleagues such as Martin Juneau and Jean-François Tanguay. These partnerships foster a collaborative environment, promoting innovative research and the development of groundbreaking medical solutions.

Conclusion

Denis Brouillette's contributions as an inventor and researcher position him as a key figure in the field of cardiac health. His patent regarding the use of methylene blue and related compounds to prevent or reverse exaggerated hemodynamic reactions showcases his dedication to advancing medical science and improving patient care. As he continues to work at the Montreal Heart Institute, Brouillette remains at the forefront of innovation in the medical field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…